Genetics and hepatitis C treatment: Towards a personalized treatment?;Genética y tratamiento de la hepatitis C: ¿hacia un tratamiento personalizado?

Gastroenterologia y Hepatologia

Volumn 34, Issue 5, 2011, Pages 352-360

  Lens García, Sabela ^a   Coto Llerena, Mairene ^a   Pérez del Pulgar Gallart, Sofía ^a   Forns Bernhardt, Xavier ^a,b  

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Genetic polymorphisms; Hepatitis C; IL28B; Liver cirrhosis

Indexed keywords

PEGINTERFERON; RIBAVIRIN;

ARTICLE; DNA POLYMORPHISM; HEALTH CARE SYSTEM; HEPATITIS C; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; TREATMENT RESPONSE; VIRAL CLEARANCE;

HEPATITIS C, CHRONIC; HUMANS; INTERLEUKINS; POLYMORPHISM, GENETIC;

EID: 79955973359     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1016/j.gastrohep.2010.12.008     Document Type: Article

References (37)

1. Karlsen TH, Melum E, Franke A. The utility of genome-wide association studies in hepatology. Hepatology. 2010;51:1833-42.
2. Veldt B.J., Heathcote E.J., Wedemeyer H., Reichen J., Hofmann W.P., Zeuzem S., et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007, 147:677-684.
3. Ghany M.G., Strader D.B., Thomas D.L., Seef L.B. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009, 49:1335-1374. American Association for the study of Liver Diseases.
4. Matsuyama N., Mishiro S., Sugimoto M., Furuichi Y., Hashimoto M., Hijikata M., et al. The dinucleotide microsatellite polymorphism of the IFNAR1 gene promoter correlates with responsiveness of hepatitis C patients to interferon. Hepatol Res. 2003, 25:221-225.
5. Tsukada H., Ochi H., Maekawa T., Abe H., Fujimoto Y., Tsuge M., et al. A polymorphism in MAPKAPK3 affects response to interferon therapy for chronic hepatitis C. Gastroenterology. 2009, 136:1796-1805.
6. Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009, 461:399-401.
7. Tanaka Y., et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009, 41:1105-1109.
8. Balagopal A, Thomas DL, Thio CL. IL28B and the control of hepatitis C virus infection. Gastroenterology. 2010;139:1865-76.
9. Thio CL, Thomas DL. Interleukin-28b: a key piece of the hepatitis C virus recovery puzzle. Gastroenterology. 2010;138:1240-43.
10. Ahlenstiel G, Booth DR, George J. IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice. J Gastroenterol. 2010;45:903-10.
11. Thomas D.L., Thio C.L., Martin M.P., Qi Y., Ge D., O'Huigin C., et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009, 461:798-801.
12. Tillmann HL, Thompson AJ, Patel K, Wiese M, Tenckhoff H, Nischalke HD, et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology. 2010;139:1586-92.
13. Montes-Cano MA, García-Lozano JR, Abad-Molina C, Romero-Gómez M, Barroso N, Aguilar-Reina J, et al. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology. 2010;52:33-7.
14. McCarthy JJ, Li JH, Thompson A, Suchindran S, Lao XQ, Patel K, et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology. 2010;138:2307-14.
15. Rauch A, Kutalik Z, Descombes P, Cai T, Di lulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010;138:1338-45.
16. Suppiah V., Moldovan M., Ahlenstiel G., Berg T., Weltman M., Abate M.L., et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009, 41:1100-1104.
17. Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, et al. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology. 2010; 52:421-9.
18. Yan K.K., Guirgis M., Dinh T., George J., Dev A., Lee A., et al. Treatment responses in Asians and Caucasians with chronic hepatitis C infection. World J Gastroenterol. 2008, 14:3416-3420.
19. Thomas D.L., Astemborski J., Rai R.M., Anania F.A., Schaefer M., Galai N., et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000, 284:450-456.
20. Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology. 2010;139:821-7.
21. Sarrazin C, Susser S, Doehring A, Lange CM, Müller T, Schlecker C, et al. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol. 2011;54:415-21.
22. Sarasin-Filipowicz M., Oakeley E.J., Duong F.H., Christen V., Terracciano L., Filipowicz W., et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A. 2008, 105:7034-7039.
23. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010;139:120-9.
24. Rallon NI, Naggie S, Benito JM, Medrano J, Restrepo C, Goldstein D, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS. 2010;24:F23-9.
25. Pineda JA, Cruz A, Rivero A, Neukam K, Salas I, Camacho A, et al. Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis. 2010;51:788-95.
26. Carrion J.A., Navasa M., García-Retortillo M., García-Pagán J.C., Crespo G., Bruguera M., et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology. 2007, 132:1746-1756.
27. Fukuhara T, Taketomi A, Motomura T, Okano S, Ninomiya A, Abe T, et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology. 2010;139:1577-85.
28. Coto-Llerena M, Pérez-del-Pulgar S, Crespo G, González P, Mensa L, Dragun J, et al. IL28B polymorphisms may influence the response to hepatitis C therapy after liver transplantation. Am J Transpl 2011. En prensa.
29. Thimme R., Blum H.E. Acute hepatitis C. Therapy with interferon alpha-2b. Internist (Berl). 2002, 43:1148-1150.
30. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD, et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology. 2010;52:1888-1896.
31. Kanda T, Imazeki F, Yokosuka O. New antiviral therapies for chronic hepatitis C. Hepatol Int. 2010;4:548-61.
32. Martin MP, Qi Y, Goedert JJ, Hussain SK, Kirk GD, Hoots WK, et al. IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection. J Infect Dis. 2010;202:1749-53.
33. Ochi H, Maekawa T, Abe H, Hayashida Y, Nakano R, Kubo M, et al. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients. Gastroenterology. 2010;139:1190-7.
34. Romeo S., Kozlitina J., Xing C., Pertsemlidis A., Cox D., Pennacchio L.A., et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008, 40:1461-1465.
35. Chalasani N, Guo X, Loomba R, Goodarzi MO, Haritunians T, Kwon S, et al. Genome-wide association study identifies variants associated with histologic features of nonalcoholic Fatty liver disease. Gastroenterology. 2010;139:1567-76.
36. Jones D.E., Donaldson P.T. Genetic factors in the pathogenesis of primary biliary cirrhosis. Clin Liver Dis. 2003, 7:841-864.
37. Karlsen TH, Franke A, Melum E, Kaser A, Hov JR, Balschun T, et al. Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology. 2010;138:1102-11.